YARROW BIOSCIENCE, INC. Net Income (Loss) Available to Common Stockholders, Diluted
YARROW BIOSCIENCE, INC. (YARW) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$29.08 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-28.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2018-03-28
- YARROW BIOSCIENCE, INC. net income (loss) available to common stockholders, diluted for fiscal 2017 was -$29.08M.
- YARROW BIOSCIENCE, INC. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$14.07M.
- YARROW BIOSCIENCE, INC. net income (loss) available to common stockholders, diluted for fiscal 2015 was -$4.61M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|
| 2017-12-31 | -$29.08M 10-K · filed 2018-03-28 |
| 2016-12-31 | -$14.07M 10-K · filed 2018-03-28 |
| 2015-12-31 | -$4.61M 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |